JP2016513094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513094A5 JP2016513094A5 JP2015556574A JP2015556574A JP2016513094A5 JP 2016513094 A5 JP2016513094 A5 JP 2016513094A5 JP 2015556574 A JP2015556574 A JP 2015556574A JP 2015556574 A JP2015556574 A JP 2015556574A JP 2016513094 A5 JP2016513094 A5 JP 2016513094A5
- Authority
- JP
- Japan
- Prior art keywords
- dll3
- cancer
- fragments
- level
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100036466 Delta-like protein 3 Human genes 0.000 claims 32
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 32
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 32
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 17
- 238000000034 method Methods 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 12
- 238000000338 in vitro Methods 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 238000012544 monitoring process Methods 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 239000003560 cancer drug Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1302447.6 | 2013-02-12 | ||
| GBGB1302447.6A GB201302447D0 (en) | 2013-02-12 | 2013-02-12 | Therapeutic and diagnostic target |
| PCT/GB2014/050407 WO2014125273A1 (en) | 2013-02-12 | 2014-02-12 | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513094A JP2016513094A (ja) | 2016-05-12 |
| JP2016513094A5 true JP2016513094A5 (cg-RX-API-DMAC7.html) | 2017-03-16 |
| JP6654046B2 JP6654046B2 (ja) | 2020-02-26 |
Family
ID=47998983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556574A Active JP6654046B2 (ja) | 2013-02-12 | 2014-02-12 | Ｄｌｌ３結合試薬を含む治療薬及び診断薬の癌標的 |
Country Status (18)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3095797B1 (en) | 2012-02-24 | 2020-05-20 | AbbVie Stemcentrx LLC | Anti dll3 antibodies and methods of use thereof |
| CN105873612A (zh) * | 2013-08-28 | 2016-08-17 | 施特姆森特克斯股份有限公司 | 改造的抗-dll3缀合物以及应用方法 |
| BR112016004242A8 (pt) | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Métodos para conjugação sítio-específica de anticorpos e composições |
| AU2015218633A1 (en) | 2014-02-21 | 2016-09-01 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
| JP6698065B2 (ja) * | 2014-07-31 | 2020-05-27 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ | 組織分布が向上した二重特異性単鎖抗体コンストラクト |
| JP6749312B2 (ja) | 2014-07-31 | 2020-09-02 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ | 最適化された種間特異的二重特異性単鎖抗体コンストラクト |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| SG10202002131PA (en) | 2015-05-21 | 2020-05-28 | Harpoon Therapeutics Inc | Trispecific binding proteins and methods of use |
| TW202346349A (zh) * | 2015-07-31 | 2023-12-01 | 德商安美基研究（慕尼黑）公司 | Dll3及cd3抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EA039325B1 (ru) * | 2016-02-03 | 2022-01-13 | Эмджен Рисерч (Мюник) Гмбх | Конструкции биспецифических антител, связывающиеся с дпб3 (dll3) и кд3 (cd3) |
| UY37105A (es) | 2016-02-03 | 2017-09-29 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| AU2018280871B2 (en) | 2017-06-08 | 2024-09-26 | Black Belt Therapeutics Ltd | CD38 modulating antibody |
| CA3073085A1 (en) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| CA3072296A1 (en) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 antibody |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| EA202090817A1 (ru) | 2017-10-13 | 2020-09-08 | Харпун Терапьютикс, Инк. | Триспецифические белки и способы их применения |
| WO2019111871A1 (en) | 2017-12-05 | 2019-06-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137 |
| US11667713B2 (en) | 2017-12-28 | 2023-06-06 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| IL323061A (en) | 2018-04-11 | 2025-10-01 | Inhibrx Biosciences Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| CN110412179A (zh) * | 2018-04-26 | 2019-11-05 | 缪荣明 | 一种液相色谱检测颗粒酶a的方法 |
| CN118146372A (zh) | 2018-05-08 | 2024-06-07 | 凡恩世制药(北京)有限公司 | 抗dll3抗体及其用途 |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| AU2019346466A1 (en) | 2018-09-25 | 2021-05-20 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| CN113166263A (zh) * | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | Dll3单域抗体及其治疗性组合物 |
| SG11202108955QA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Antibody molecules that bind to nkp30 and uses thereof |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| EP3908679A1 (en) * | 2019-03-08 | 2021-11-17 | OncoLab Diagnostics GmbH | Cancer diagnosis and prognosis |
| CN113795262A (zh) * | 2019-04-08 | 2021-12-14 | 东莞凡恩世生物医药有限公司 | 人源化抗dll3嵌合抗原受体及其用途 |
| EP3819312A1 (en) * | 2019-11-10 | 2021-05-12 | Amgen, Inc | Dosing regimen for anti-dll3 agents |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| US12486331B2 (en) | 2020-01-31 | 2025-12-02 | Gensun Biopharma Inc. | Bispecific T cell engagers |
| CN115643806A (zh) * | 2020-01-31 | 2023-01-24 | 璟尚生物制药公司 | 双特异性t细胞接合器 |
| AR121695A1 (es) | 2020-03-31 | 2022-06-29 | Chugai Pharmaceutical Co Ltd | Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos |
| US20240124574A1 (en) * | 2021-02-05 | 2024-04-18 | Phanes Therapeutics, Inc. | Bispecific Antibodies with Charge Pairs and Uses Thereof |
| PE20241133A1 (es) * | 2021-09-17 | 2024-05-24 | Wuxi Biologics Ireland Ltd | Moleculas de union a d3 y usos de estas |
| KR20250036727A (ko) * | 2022-05-04 | 2025-03-14 | 얼리 인크. | 질환에 걸린 세포를 국재화시키고/거나 치료하기 위한 표면-발현가능한 활성화가능한 에피토프를 사용하는 방법 |
| WO2025061132A1 (en) * | 2023-09-21 | 2025-03-27 | Concept To Medicine Biotech Co., Ltd. | Anti-dll3 antibodies and uses thereof |
| WO2025190281A1 (en) * | 2024-03-11 | 2025-09-18 | Lepu Biopharma Co., Ltd. | Anti-dll3 antibodies and uses thereof |
| CN119841904A (zh) * | 2025-03-18 | 2025-04-18 | 中国科学院近代物理研究所 | 一种dll3亲和肽及其应用 |
| CN120168667A (zh) * | 2025-03-18 | 2025-06-20 | 中国科学院近代物理研究所 | 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| GB9106048D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccines |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| AU8874591A (en) | 1990-10-22 | 1992-05-20 | Abbott Laboratories | Stabilized anoxic diagnostic reagent solution |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| DK1471142T3 (da) | 1991-04-10 | 2009-03-09 | Scripps Research Inst | Heterodimere receptor-biblioteker under anvendelse af fagemider |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| EP1024191B8 (en) | 1991-12-02 | 2008-11-05 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| CA2148252C (en) | 1992-10-30 | 2007-06-12 | Roger Brent | Interaction trap system for isolating novel proteins |
| US5807683A (en) | 1992-11-19 | 1998-09-15 | Combichem, Inc. | Combinatorial libraries and methods for their use |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US5738996A (en) | 1994-06-15 | 1998-04-14 | Pence, Inc. | Combinational library composition and method |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| GB9608510D0 (en) | 1996-04-25 | 1996-07-03 | Medical Res Council | Calcium dependent binding ligands |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| ATE472609T1 (de) | 2001-04-26 | 2010-07-15 | Amgen Mountain View Inc | Kombinatorische bibliotheken von monomerdomänen |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
| CA2447851C (en) | 2001-06-28 | 2012-08-28 | Domantis Limited | Dual-specific ligand and its use |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| AU2003286002B2 (en) | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| AU2003290330A1 (en) | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| AU2004239065B2 (en) | 2003-05-14 | 2008-05-15 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| CA2523716C (en) | 2003-05-31 | 2014-11-25 | Micromet Ag | Human anti-human cd3 binding molecules |
| AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| JP2008520207A (ja) | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
| JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| BRPI0611445A2 (pt) | 2005-05-09 | 2010-09-08 | Glycart Biotechnology Ag | molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| EA016609B1 (ru) | 2005-11-28 | 2012-06-29 | Генмаб А/С | Рекомбинантные моновалентные антитела и способы их получения |
| WO2007111733A2 (en) * | 2005-12-16 | 2007-10-04 | Genentech, Inc. | Method for diagnosing, prognosing and treating glioma |
| EP1973945A4 (en) | 2006-01-16 | 2009-11-18 | Compugen Ltd | NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND METHOD FOR THEIR APPLICATION IN DIAGNOSIS |
| US7862813B2 (en) * | 2006-07-29 | 2011-01-04 | Bjork Jr Robert Lamar | Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug |
| SG182234A1 (en) | 2007-04-03 | 2012-07-30 | Amgen Res Munich Gmbh | Cross-species-specific cd3-epsilonbinding domain |
| JP2011509079A (ja) | 2007-12-24 | 2011-03-24 | オックスフォード ビオトヘラペウトイクス エルティーディー． | エフリンａ型受容体１０タンパク質 |
| US8557965B2 (en) * | 2008-04-07 | 2013-10-15 | Ablynx N.V. | Single variable domains against notch pathway members |
| PT2307051E (pt) | 2008-07-08 | 2015-05-21 | Oncomed Pharm Inc | Antagonistas e agentes de ligação a notch e métodos de utilização dos mesmos |
| US20120244161A1 (en) | 2009-09-18 | 2012-09-27 | Gerhard Zugmeier | DOSAGE REGIMEN FOR ADMINISTERING AN EpCAMxCD3 BISPECIFIC ANTIBODY |
| LT3342786T (lt) | 2010-01-29 | 2021-10-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antikūnai |
| US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
| CN103796677B (zh) * | 2011-04-20 | 2019-08-16 | 健玛保 | 针对her2和cd3的双特异性抗体 |
| CN107722124A (zh) | 2011-05-21 | 2018-02-23 | 宏观基因有限公司 | 能够与人和非人cd3结合的cd3结合分子 |
| US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
| EP3095797B1 (en) * | 2012-02-24 | 2020-05-20 | AbbVie Stemcentrx LLC | Anti dll3 antibodies and methods of use thereof |
-
2013
- 2013-02-12 GB GBGB1302447.6A patent/GB201302447D0/en not_active Ceased
-
2014
- 2014-02-12 AU AU2014217611A patent/AU2014217611B2/en not_active Ceased
- 2014-02-12 US US14/766,992 patent/US20160032006A1/en not_active Abandoned
- 2014-02-12 HU HUE14705561A patent/HUE050828T2/hu unknown
- 2014-02-12 EP EP14705561.0A patent/EP2956483B1/en not_active Revoked
- 2014-02-12 ES ES14705561T patent/ES2813360T3/es active Active
- 2014-02-12 CN CN201480020452.4A patent/CN105143266B/zh active Active
- 2014-02-12 EA EA201500835A patent/EA034182B1/ru not_active IP Right Cessation
- 2014-02-12 KR KR1020157024805A patent/KR102167550B1/ko not_active Expired - Fee Related
- 2014-02-12 MX MX2015010372A patent/MX370597B/es active IP Right Grant
- 2014-02-12 JP JP2015556574A patent/JP6654046B2/ja active Active
- 2014-02-12 CA CA2900134A patent/CA2900134A1/en not_active Abandoned
- 2014-02-12 EP EP20175944.6A patent/EP3736293A1/en not_active Withdrawn
- 2014-02-12 WO PCT/GB2014/050407 patent/WO2014125273A1/en not_active Ceased
- 2014-02-12 PL PL14705561T patent/PL2956483T3/pl unknown
- 2014-02-12 DK DK14705561.0T patent/DK2956483T3/da active
-
2015
- 2015-07-16 IL IL239983A patent/IL239983B/en active IP Right Grant
- 2015-08-07 PH PH12015501744A patent/PH12015501744A1/en unknown
- 2015-08-07 CL CL2015002223A patent/CL2015002223A1/es unknown
-
2018
- 2018-03-07 US US15/914,432 patent/US20180201691A1/en not_active Abandoned
-
2020
- 2020-11-20 US US16/953,459 patent/US20210079114A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513094A5 (cg-RX-API-DMAC7.html) | ||
| Ameling et al. | Associations of circulating plasma microRNAs with age, body mass index and sex in a population-based study | |
| JP2016500110A5 (cg-RX-API-DMAC7.html) | ||
| EP4282405A3 (en) | Detection of cancer biomarkers using nanoparticles | |
| CY1122871T1 (el) | Μεθοδος ποσοτικου προσδιορισμου για την εκφραση της pd-l1 | |
| EA201070738A1 (ru) | Композиции и способы детекции tiab | |
| Kofla-Dłubacz et al. | Metalloproteinase-3 and-9 as novel markers in the evaluation of ulcerative colitis activity in children | |
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| WO2009090553A3 (en) | Compositions and methods of detecting post-stop peptides | |
| WO2013068374A3 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment | |
| EP3208617A3 (en) | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment | |
| JP2012500389A5 (cg-RX-API-DMAC7.html) | ||
| WO2014036495A3 (en) | Diagnostic assays and kits for detection of folate receptor 1 | |
| JP2016536012A5 (cg-RX-API-DMAC7.html) | ||
| RU2015102194A (ru) | Способы лечения связанных с fgfr3 состояний | |
| JP2014521089A5 (cg-RX-API-DMAC7.html) | ||
| Bahadır et al. | Biosensor technologies for analyses of food contaminants | |
| JP2015210268A5 (cg-RX-API-DMAC7.html) | ||
| JP2013178260A5 (cg-RX-API-DMAC7.html) | ||
| JP2017505897A5 (cg-RX-API-DMAC7.html) | ||
| WO2011052906A3 (en) | Use of eif3m for the diagnosis and treatment of cancer | |
| JP2009516178A5 (cg-RX-API-DMAC7.html) | ||
| Zhang et al. | Prognostic significance of combining VEGFA, FLT1 and KDR mRNA expression in lung cancer | |
| WO2008089135A3 (en) | Identification of biomarkers predictive of dasatinib effects in cancer cells | |
| Schlaeger et al. | Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval? |